| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Studies |
Medical Department M (Endocrinology and Diabetes) (C.H.G., S.F., J.S.C.) and Pediatric Department A (R.W.N.), Aarhus University Hospital, Kommunehospitalet, DK-8000 Aarhus C, Denmark
Address all correspondence and requests for reprints to: Dr. Claus Højbjerg Gravholt, Medical Department M (Endocrinology and Diabetes), Kommunehospitalet, DK-8000 Aarhus C, Denmark. E-mail: cg{at}afdm.aau.dk
The objectives of this study were to 1) study the GH-insulin-like growth factor (IGF) axis in adult untreated Turners syndrome compared to that in age-matched controls, 2) examine the effects of sex hormone substitution on this axis, 3) study the effects of route of administration of 17ß-estradiol on the measured variables, and 4) examine the effects of sex steroids on hepatic function in Turner patients. Twenty-seven patients with Turners syndrome were evaluated before and during sex hormone replacement, and an age-matched control group (n = 24) was evaluated once. Main outcome variables were GH and other measures of the GH-IGF axis, body composition, maximal oxygen uptake, sex hormone-binding globulin, and hepatic enzymes and proteins.
The integrated 24-h GH concentration (IC-GH; micrograms per L/24 h) was
reduced in women with Turners syndrome (T) compared to controls [C;
mean ± SD, 18.3 ± 12.0 (T) vs.
37.2 ± 29.7 (C); P = 0.007]. However,
multiple regression revealed that fat-free mass (FFM) and maximal
oxygen uptake were significant explanatory variables (joint r =
0.77; P < 0.0005), accounting for 60% of the
variance in the 24-h IC-GH. This association was also present in
controls. After adjustment for these two variables, any difference in
GH concentration between Turner patients and controls disappeared.
Serum IGF-I and IGF-II were identical in Turner patients and controls
despite the difference in 24-h IC-GH. The level of GH-binding protein
(GHBP; nanomoles per L) was higher in Turner women [1.87 ± 0.72
(T) vs. 1.22 ± 0.33 (C); P =
0.0005]; after adjustment for FFM, the difference in GHBP levels
disappeared between Turner patients and controls. During sex hormone
treatment a significant increase was seen in the 24-h IC-GH
(P = 0.02), FFM (percentage of weight;
P < 0.0005) and maximal oxygen uptake (milliliters
of O2 per kg/min; P = 0.02). Serum
IGF-I was unchanged, whereas serum IGF-II (micrograms per L) decreased
significantly [Turner, basal (TB), vs. Turner,
treatment (TT), 860 ± 135 vs. 823 ±
150; P = 0.04]. Alanine aminotransferase (units
per L),
-glutamyl transferase (units per L), and alkaline
phosphatase (units per L) were significantly elevated during the basal
study period, and all decreased during treatment [alanine
aminotransferase, 55 ± 55 (TB) vs. 30
± 20 (TT; P = 0.006);
-glutamyl
transferase, 92 ± 98 (TB) vs. 43 ±
65 (TT; P = 0.003); alkaline
phosphatase, 211 ± 113 (TB) vs. 175
± 54 (TT); P = 0.06]. The route of
administration of 17ß-estradiol did not affect its actions.
In conclusion, we found the GH-IGF axis in Turners syndrome to be normal, with body composition and physical fitness exerting the same modifying effects on this axis as seen in the normal population. Sex hormone replacement in Turners syndrome is associated with normalizing effects on the GH-IGF axis, body composition, physical fitness, and hepatic function. The lowering of hepatic enzymes is a surprising and hitherto undiscovered action of sex steroids. Finally, the route of administration of 17ß-estradiol is of minor importance in Turners syndrome.
This article has been cited by other articles:
![]() |
B. E. Hjerrild, K. H. Mortensen, and C. H. Gravholt Turner syndrome and clinical treatment Br. Med. Bull., June 1, 2008; 86(1): 77 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Gravholt, H. E. Poulsen, P. Ott, J. S. Christiansen, and H. Vilstrup Quantitative liver functions in Turner syndrome with and without hormone replacement therapy Eur. J. Endocrinol., June 1, 2007; 156(6): 679 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Bondy and for The Turner Syndrome Consensus Study Group Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 10 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Gravholt, B. E. Hjerrild, L. Mosekilde, T. K. Hansen, L. M. Rasmussen, J. Frystyk, A. Flyvbjerg, and J. S. Christiansen Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur. J. Endocrinol., October 1, 2006; 155(4): 583 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Gravholt, R. W. Naeraa, K. Brixen, K. W. Kastrup, L. Mosekilde, J. O. L. Jorgensen, and J. S. Christiansen Short-Term Growth Hormone Treatment in Girls With Turner Syndrome Decreases Fat Mass and Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study Pediatrics, November 1, 2002; 110(5): 889 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Saenger, K. A. Wikland, G. S. Conway, M. Davenport, C. H. Gravholt, R. Hintz, O. Hovatta, M. Hultcrantz, K. Landin-Wilhelmsen, A. Lin, et al. Recommendations for the Diagnosis and Management of Turner Syndrome J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3061 - 3069. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Wilson Regulation of the Growth Hormone-Insulin-Like Growth Factor I Axis in Developing and Adult Monkeys Is Affected by Estradiol Replacement and Supplementation with Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2018 - 2028. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |